Indeed, anti-TNF and JAK inhibitors are associated with reduced vaccine-induced antibody-binding and viral neutralization following SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] vaccination and anti-TNF therapy is associated with increased risk of post-vaccination breakthrough infection.3–6. Here, TNF is linked to infection.